Cardiovascular Genetic Profile – F5, F2, MTHFR, APOE, ACE, PAI-1, FXIII & NOS3

Product detailed description

The Cardiovascular Genetic Profile is an expanded DNA test that analyzes inherited genetic factors associated with heart and blood vessel health, blood clotting, lipid metabolism, and blood pressure regulation. It provides insights into selected genetic variants involved in biological processes important for cardiovascular function.

Cardiovascular diseases are among the most common health conditions worldwide. Their development is influenced by a complex combination of genetic predispositions, lifestyle, and other risk factors. Genetic differences may contribute to variations in blood coagulation, cholesterol metabolism, and vascular regulation.

The test analyzes eight genes or genetic regions – F5, F2, MTHFR, APOE, ACE, PAI-1, FXIII, and NOS3. Certain variants have well-established clinical associations with specific health risks, while others are primarily studied for their potential contributions to cardiovascular biology.

What does the genetic test analyze?

• F5 – Factor V Leiden: A genetic variant associated with increased blood clotting tendency and a higher risk of venous thrombosis.

• F2 – Prothrombin: Certain variants may increase susceptibility to blood clot formation, particularly in the venous system.

• MTHFR – Folate and homocysteine metabolism: A gene involved in vitamin B9 processing and homocysteine metabolism.

• APOE – Cholesterol and lipid metabolism: Genetic variants associated with lipoprotein metabolism and differences in blood lipid levels.

• ACE – Blood pressure regulation: A gene involved in the renin-angiotensin system, which contributes to blood pressure and fluid balance.

• PAI-1 (SERPINE1) – Blood clot breakdown: A gene involved in fibrinolysis, the body's natural process of dissolving blood clots.

• FXIII – Blood clot stabilization: Genetic variants associated with coagulation factor XIII, which helps stabilize blood clots.

• NOS3 – Vascular function: A gene involved in nitric oxide production, contributing to blood vessel relaxation and vascular tone regulation.

Who may benefit from cardiovascular genetic testing?

• Individuals interested in genetic factors related to cardiovascular health.

• People with a family history of venous thrombosis or inherited thrombophilia when genetic testing is medically indicated.

• Those interested in the genetics of cholesterol metabolism, blood pressure, and vascular function.

• Individuals seeking to understand inherited differences in blood coagulation pathways.

• People looking for supplementary genetic information as part of an individualized cardiovascular health assessment.

What can the results reveal?

The Cardiovascular Genetic Profile provides an overview of selected inherited genetic variants associated with blood coagulation, lipid metabolism, blood pressure regulation, and vascular function.

For the F5 and F2 genes, identifying specific risk-associated variants may provide clinically meaningful information about inherited susceptibility to venous thrombosis. However, the value of genetic testing for guiding preventive or treatment decisions depends on the individual's clinical circumstances.

Results from the remaining genes primarily provide supplementary information about biological pathways involved in cardiovascular function. Their ability to independently predict specific cardiovascular diseases is limited.

Important: This genetic profile cannot independently determine an individual's overall risk of heart attack, stroke, or other cardiovascular diseases. Common MTHFR, PAI-1, and FXIII variants are not recommended as standard markers of inherited thrombophilia. Results should be interpreted alongside personal and family medical history, blood pressure, cholesterol levels, and other clinical factors.

This test does not replace professional cardiological or hematological evaluation. Its clinical significance should be assessed by a qualified healthcare professional.